About UsCommitted to developing a new generation of medicines that go beyond the current standard of care

VistaGen Therapeutics is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders that are disrupting the lives of tens of millions of people around the world.

Our VisionStriving for a world no longer gripped by anxiety, fear and depression

VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.

Large Unmet Mental Health Care Needs in Anxiety and Depression

23.7 Million1

Americans suffer from Social Anxiety Disorder

19.4 Million2

Adults in the US had at least one major Depressive Episode

264 Million3

People World-wide suffer from Depression

1. Kantar Health. September 2020. NATIONAL HEALTH AND WELLNESS SURVEY, 2020. [US]. Malvern, PA | 2. Substance Abuse and Mental Health Services Administration, 2020 | 3. World Health Organization

Pipeline VistaGen Products in Development

For Anxiety Disorders

PH94B is an innovative, odorless, rapid-onset CNS pherine nasal spray with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with currently prescribed products.

For Depression

PH10 is an investigational CNS pherine nasal spray with potential to be a fast -acting stand-alone treatment for neuropsychiatric indications involving depression.

For CNS Diseases & Disorders

AV-101 (4-Cl-KYN) is an investigational prodrug designed to be orally administered and to target the NMDA receptor that can be associated with numerous CNS diseases and disorders.